NYSE:NVO

Novo Nordisk A/S Competitors

$69.62
-0.50 (-0.71 %)
(As of 04/12/2021 11:40 AM ET)
Add
Compare
Today's Range
$69.31
Now: $69.62
$69.72
50-Day Range
$67.06
MA: $70.29
$75.09
52-Week Range
$58.36
Now: $69.62
$75.86
Volume13,431 shs
Average Volume1.02 million shs
Market Capitalization$163.94 billion
P/E Ratio26.17
Dividend Yield1.90%
Beta0.46

Competitors

Novo Nordisk A/S (NYSE:NVO) Vs. JNJ, ABT, PFE, NVS, MRK, and ABBV

Should you be buying NVO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Novo Nordisk A/S, including Johnson & Johnson (JNJ), Abbott Laboratories (ABT), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), and AbbVie (ABBV).

Johnson & Johnson (NYSE:JNJ) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Johnson & Johnson and Novo Nordisk A/S, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson031102.79
Novo Nordisk A/S25302.10

Johnson & Johnson presently has a consensus target price of $180.6429, indicating a potential upside of 11.98%. Novo Nordisk A/S has a consensus target price of $72.00, indicating a potential upside of 3.31%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, research analysts clearly believe Johnson & Johnson is more favorable than Novo Nordisk A/S.

Volatility and Risk

Johnson & Johnson has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Insider & Institutional Ownership

67.3% of Johnson & Johnson shares are held by institutional investors. Comparatively, 5.9% of Novo Nordisk A/S shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dividends

Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.5%. Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.9%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 54.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and Novo Nordisk A/S has raised its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Johnson & Johnson and Novo Nordisk A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson21.01%34.64%13.40%
Novo Nordisk A/S32.65%71.46%31.34%

Earnings and Valuation

This table compares Johnson & Johnson and Novo Nordisk A/S's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.06 billion5.19$15.12 billion$8.6818.62
Novo Nordisk A/S$18.30 billion8.96$5.84 billion$2.4628.30

Johnson & Johnson has higher revenue and earnings than Novo Nordisk A/S. Johnson & Johnson is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Johnson & Johnson beats Novo Nordisk A/S on 12 of the 17 factors compared between the two stocks.

Novo Nordisk A/S (NYSE:NVO) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Profitability

This table compares Novo Nordisk A/S and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novo Nordisk A/S32.65%71.46%31.34%
Abbott Laboratories10.50%18.19%8.29%

Insider and Institutional Ownership

5.9% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.9%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Novo Nordisk A/S pays out 54.1% of its earnings in the form of a dividend. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S has raised its dividend for 1 consecutive years and Abbott Laboratories has raised its dividend for 49 consecutive years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Novo Nordisk A/S and Abbott Laboratories, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novo Nordisk A/S25302.10
Abbott Laboratories111502.82

Novo Nordisk A/S currently has a consensus price target of $72.00, suggesting a potential upside of 3.31%. Abbott Laboratories has a consensus price target of $122.0556, suggesting a potential upside of 0.96%. Given Novo Nordisk A/S's higher possible upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than Abbott Laboratories.

Valuation & Earnings

This table compares Novo Nordisk A/S and Abbott Laboratories' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Nordisk A/S$18.30 billion8.96$5.84 billion$2.4628.30
Abbott Laboratories$31.90 billion6.73$3.69 billion$3.2437.43

Novo Nordisk A/S has higher earnings, but lower revenue than Abbott Laboratories. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Novo Nordisk A/S has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Summary

Abbott Laboratories beats Novo Nordisk A/S on 9 of the 17 factors compared between the two stocks.

Novo Nordisk A/S (NYSE:NVO) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Earnings and Valuation

This table compares Novo Nordisk A/S and Pfizer's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Nordisk A/S$18.30 billion8.96$5.84 billion$2.4628.30
Pfizer$51.75 billion3.95$16.27 billion$2.9512.41

Pfizer has higher revenue and earnings than Novo Nordisk A/S. Pfizer is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Novo Nordisk A/S has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Dividends

Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.9%. Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.3%. Novo Nordisk A/S pays out 54.1% of its earnings in the form of a dividend. Pfizer pays out 52.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S has increased its dividend for 1 consecutive years and Pfizer has increased its dividend for 1 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.

Insider and Institutional Ownership

5.9% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Novo Nordisk A/S and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novo Nordisk A/S32.65%71.46%31.34%
Pfizer17.85%24.88%9.32%

Analyst Ratings

This is a summary of recent ratings for Novo Nordisk A/S and Pfizer, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novo Nordisk A/S25302.10
Pfizer010302.23

Novo Nordisk A/S currently has a consensus price target of $72.00, indicating a potential upside of 3.31%. Pfizer has a consensus price target of $38.5714, indicating a potential upside of 5.59%. Given Pfizer's stronger consensus rating and higher probable upside, analysts plainly believe Pfizer is more favorable than Novo Nordisk A/S.

Summary

Pfizer beats Novo Nordisk A/S on 10 of the 15 factors compared between the two stocks.

Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Novartis and Novo Nordisk A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novartis14.71%24.39%10.59%
Novo Nordisk A/S32.65%71.46%31.34%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Novartis and Novo Nordisk A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novartis24602.33
Novo Nordisk A/S25302.10

Novartis currently has a consensus target price of $108.50, suggesting a potential upside of 23.97%. Novo Nordisk A/S has a consensus target price of $72.00, suggesting a potential upside of 3.31%. Given Novartis' stronger consensus rating and higher possible upside, analysts clearly believe Novartis is more favorable than Novo Nordisk A/S.

Earnings & Valuation

This table compares Novartis and Novo Nordisk A/S's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$47.50 billion4.22$11.73 billion$5.2416.70
Novo Nordisk A/S$18.30 billion8.96$5.84 billion$2.4628.30

Novartis has higher revenue and earnings than Novo Nordisk A/S. Novartis is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Novartis has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Insider & Institutional Ownership

9.9% of Novartis shares are owned by institutional investors. Comparatively, 5.9% of Novo Nordisk A/S shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dividends

Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.4%. Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.9%. Novartis pays out 39.7% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 54.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis has increased its dividend for 1 consecutive years and Novo Nordisk A/S has increased its dividend for 1 consecutive years. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Novartis beats Novo Nordisk A/S on 11 of the 16 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.

Risk and Volatility

Merck & Co., Inc. has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.

Earnings & Valuation

This table compares Merck & Co., Inc. and Novo Nordisk A/S's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.13$9.84 billion$5.1914.73
Novo Nordisk A/S$18.30 billion8.96$5.84 billion$2.4628.30

Merck & Co., Inc. has higher revenue and earnings than Novo Nordisk A/S. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 5.9% of Novo Nordisk A/S shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Merck & Co., Inc. and Novo Nordisk A/S, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021202.86
Novo Nordisk A/S25302.10

Merck & Co., Inc. currently has a consensus price target of $95.9167, suggesting a potential upside of 25.74%. Novo Nordisk A/S has a consensus price target of $72.00, suggesting a potential upside of 3.31%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, equities analysts plainly believe Merck & Co., Inc. is more favorable than Novo Nordisk A/S.

Profitability

This table compares Merck & Co., Inc. and Novo Nordisk A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.24.33%53.83%16.83%
Novo Nordisk A/S32.65%71.46%31.34%

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.9%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 54.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and Novo Nordisk A/S has increased its dividend for 1 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Merck & Co., Inc. beats Novo Nordisk A/S on 10 of the 16 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Profitability

This table compares AbbVie and Novo Nordisk A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie18.16%439.24%13.22%
Novo Nordisk A/S32.65%71.46%31.34%

Analyst Ratings

This is a breakdown of current recommendations and price targets for AbbVie and Novo Nordisk A/S, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie121402.76
Novo Nordisk A/S25302.10

AbbVie currently has a consensus target price of $115.75, indicating a potential upside of 7.21%. Novo Nordisk A/S has a consensus target price of $72.00, indicating a potential upside of 3.31%. Given AbbVie's stronger consensus rating and higher possible upside, equities research analysts clearly believe AbbVie is more favorable than Novo Nordisk A/S.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.8%. Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.9%. AbbVie pays out 58.2% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 54.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 49 consecutive years and Novo Nordisk A/S has increased its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Volatility & Risk

AbbVie has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Institutional and Insider Ownership

67.5% of AbbVie shares are owned by institutional investors. Comparatively, 5.9% of Novo Nordisk A/S shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares AbbVie and Novo Nordisk A/S's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion5.74$7.88 billion$8.9412.11
Novo Nordisk A/S$18.30 billion8.96$5.84 billion$2.4628.30

AbbVie has higher revenue and earnings than Novo Nordisk A/S. AbbVie is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Novo Nordisk A/S on 12 of the 17 factors compared between the two stocks.


Novo Nordisk A/S Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.7$161.65-0.2%$424.52 billion$82.06 billion25.42
Abbott Laboratories logo
ABT
Abbott Laboratories
2.4$121.28-0.3%$214.18 billion$31.90 billion64.17
Pfizer logo
PFE
Pfizer
2.3$36.62-0.1%$204.14 billion$51.75 billion23.63
Novartis logo
NVS
Novartis
2.0$87.52-0.0%$200.38 billion$47.50 billion28.32
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.4$76.44-0.2%$193.09 billion$46.84 billion16.91
AbbVie logo
ABBV
AbbVie
2.8$108.25-0.7%$189.79 billion$33.27 billion22.89
Eli Lilly and logo
LLY
Eli Lilly and
2.1$181.90-1.4%$176.92 billion$22.32 billion29.72
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$62.40-0.3%$139.87 billion$26.15 billion-567.22
AstraZeneca logo
AZN
AstraZeneca
2.1$49.62-0.6%$131.07 billion$24.38 billion51.69Analyst Downgrade
Sanofi logo
SNY
Sanofi
1.5$50.49-0.6%$127.84 billion$40.00 billion21.58
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.1$36.15-1.4%$98.68 billion$43.10 billion11.12
Zoetis logo
ZTS
Zoetis
2.2$162.13-1.4%$75.93 billion$6.26 billion48.11
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$213.87-0.2%$55.46 billion$4.16 billion27.00Analyst Report
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$17.17-0.5%$54.38 billion$30.20 billion57.24
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$473.25-0.4%$50.91 billion$7.86 billion17.30News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$154.56-0.3%$34.08 billion$4.99 billion36.11
BeiGene logo
BGNE
BeiGene
1.3$302.21-2.0%$28.23 billion$428.21 million-14.95
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$41.55-1.8%$25.69 billionN/A0.00Analyst Revision
Genmab A/S logo
GMAB
Genmab A/S
1.4$33.49-2.1%$22.42 billion$804.57 million25.96
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.6$88.64-3.2%$20.50 billion$1.30 billion24.22
Catalent logo
CTLT
Catalent
1.7$109.54-0.3%$18.60 billion$3.09 billion69.77
CureVac logo
CVAC
CureVac
0.6$91.46-3.9%$16.43 billionN/A0.00Gap Down
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$136.55-1.2%$16.22 billion$219.75 million-17.44
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$29.48-0.9%$14.07 billion$3.07 billion-51.72
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$77.34-0.3%$14.01 billion$1.70 billion17.70Insider Selling
Grifols logo
GRFS
Grifols
1.3$17.73-1.5%$12.38 billion$5.71 billion15.83
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.96-0.7%$12.06 billion$16.89 billion-2.98
Zai Lab logo
ZLAB
Zai Lab
1.4$126.23-5.1%$11.75 billion$12.98 million-41.66
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$30.29-1.6%$10.95 billion$8.60 billion-5.56
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$66.43-3.8%$10.63 billion$2.32 billion54.90Analyst Upgrade
News Coverage
Gap Down
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$161.29-0.1%$9.09 billion$2.16 billion50.88
United Therapeutics logo
UTHR
United Therapeutics
1.5$201.31-1.0%$9.06 billion$1.45 billion19.05Analyst Revision
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.8$33.30-4.1%$8.93 billionN/A0.00
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$164.86-3.2%$8.62 billion$3.34 million-21.41
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.02-0.9%$8.12 billion$40.56 million-15.84Analyst Report
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$101.14-2.3%$6.93 billion$103.71 million-23.04Gap Up
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$217.68-0.1%$6.83 billion$311.33 million-126.56
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$123.85-1.4%$6.75 billion$14.98 million-15.09
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$62.24-0.1%$6.45 billion$87.99 million-74.10News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$43.48-3.0%$6.30 billion$150,000.00-20.51
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.67-1.7%$5.97 billion$1.12 billion86.81
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$69.78-1.1%$5.60 billion$380.83 million-8.92
Allakos logo
ALLK
Allakos
1.7$104.47-0.5%$5.58 billionN/A-38.13
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$93.57-0.6%$5.46 billion$66.51 million17.26
Perrigo logo
PRGO
Perrigo
2.5$40.72-0.5%$5.41 billion$4.84 billion-678.55
Schrödinger logo
SDGR
Schrödinger
1.5$72.84-1.5%$5.17 billion$85.54 million0.00Insider Selling
Galapagos logo
GLPG
Galapagos
1.3$77.17-0.8%$5.10 billion$1.00 billion-11.69
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$56.35-0.3%$4.68 billionN/A0.00
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.53-2.8%$4.47 billion$6.87 million-7.20Analyst Report
Analyst Revision
Gap Up
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.92-0.8%$4.31 billionN/A-5.70Analyst Revision
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.